Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Stock Has Consensus Target Price of $11.00 According to Brokerages

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) has received an average rating of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $11.00.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Tuesday, October 6th.

Institutional Trading of Evaxion A/S

Several hedge funds and other institutional investors have recently bought and sold shares of EVAX. Annis Gardner Whiting Capital Advisors LLC bought a new stake in Evaxion A/S in the first quarter worth $112,000. Renaissance Technologies LLC purchased a new stake in Evaxion A/S during the first quarter valued at about $146,000. Finally, Rathbones Group PLC purchased a new stake in Evaxion A/S during the first quarter valued at about $170,000. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Evaxion A/S Price Performance

Shares of EVAX stock traded up $0.03 on Friday, reaching $2.83. The company’s stock had a trading volume of 74,536 shares, compared to its average volume of 44,088. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.69. Evaxion A/S has a 12-month low of $2.72 and a 12-month high of $9.50. The company has a market capitalization of $25.53 million, a P/E ratio of -2.34 and a beta of 0.50. The stock’s 50 day simple moving average is $3.14 and its 200-day simple moving average is $3.46.

About Evaxion A/S

Evaxion A/S is a Denmark-based biotechnology company developing artificial intelligence-driven immunotherapies. The company’s technology is designed to identify disease-specific targets, known as antigens, and support the development of personalized treatments that stimulate a patient’s immune system to recognize and attack diseased cells or pathogens.

Evaxion’s research programs have focused primarily on personalized cancer immunotherapies, including EVX-01, as well as vaccines and immunotherapies for infectious diseases caused by bacteria and viruses.